DLL4 and neoplasm: A phase Ib trial of Demcizumab targeted DLL4 combined with standard chemotherapy resulted in 50% patients with objective tumor response by regulating Notch signaling and angiogenesis in metastatic non-squamous non-small cell lung cancer (27).